AK
Therapeutic Areas
Anixa Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Breast Cancer Vaccine | Triple-Negative Breast Cancer (TNBC) - Treatment & Prevention | Phase 1 |
| Ovarian Cancer Vaccine | Ovarian Cancer - Treatment & Prevention | Discovery/Preclinical |
| CER-T Immunotherapy | Cancer (Undisclosed) | Preclinical/Discovery |
| Lung Cancer Vaccine | Lung Cancer | Discovery |
| Colon Cancer Vaccine | Colon Cancer | Discovery |
| Prostate Cancer Vaccine | Prostate Cancer | Discovery |
Leadership Team at Anixa Biosciences
MC
Michael Catelani
President, COO & CFO
PD
Pamela D. Garzone, Ph.D.
Chief Development Officer
LT
Lew Titterton
Lead Independent Director
AB
Arnold Baskies, MD
Director
EG
Emily Gottschalk
Director
MS
Michael Shepard, Ph.D.
Scientific Advisor
JC
Jose Conejo-Garcia, MD, Ph.D.
Scientific Advisor
MD
Marco Davila, MD, Ph.D.
Scientific Advisor
DA
Daniel Abate-Daga, Ph.D.
Scientific Advisor
LK
Linda Kelley, Ph.D.
Scientific Advisor